Screen Shot 2018-08-01 at 4.01.55 PM.png

About oncolytic viruses

Oncolytic viruses (OVs) specifically replicate in tumour cells and causes cell lysis without damaging or effecting healthy normal cells

Molecular virology technology has made it possible to transform & re-organize the viral genome, manipulated to become 'armed'

The 'armed' OV can block tumour-induced immunosuppression & activate anti-tumour effects of the immune cells, thus drastically modifying the tumour's micro-environment in order to target and eliminate tumour cells

VIROGIN's novel strategy

Current oncolytic viruses (OVs) possess limited clinical efficacy & solely depend upon intratumoural delivery.

Virogin's innovative strategy ensures:

  1. Targeted tumour specificity mechanism of current OVs
  2. Virogin's new generation of OVs are "Regulation-based selection" or "Active selection" → Enhancement-based selection
  3. Simultaneous enhancement of oncolytic activity and tumour specificity - making IV delivery possible

About oncolytic viruses

Oncolytic viruses (OVs) specifically replicate in tumour cells and causes cell lysis without damaging or effecting healthy normal cells.

Molecular virology technology has made it possible to transform & re-organize the viral genome, manipulated to become 'armed'. The 'armed' OV can block tumour-induced immunosuppression & activate anti-tumour effects of the immune cells, thus drastically modifying the tumour's micro-environment in order to target and eliminate tumour cells

VIROGIN's novel strategy

Current oncolytic viruses (OVs) possess limited clinical efficacy & solely depend upon intratumoural delivery.

Virogin's innovative strategy ensures:

  1. Targeted tumour specificity mechanism of current OVs
  2. Virogin's new generation of OVs are "Regulation-based selection" or "Active selection" → Enhancement-based selection
  3. Simultaneous enhancement of oncolytic activity and tumour specificity - making IV delivery possible